Rheumatic diseases and coronavirus infection: levilimab use experience
E. V. Kalinina,
I. V. Lekareva,
M. S. Zvonorenko,
A. L. Emelianova,
I. V. Kostryukova,
E. V. Scherbinina,
A. R. Babaeva https://doi.org/10.33667/2078-5631-2021-16-7-12
Abstract
Background. Rheumatic diseases (RD) of autoimmune origin are considered as an important risk factor for infectious processes due to characteristic native immune system disorder, as well as due to the adverse effect of immunosuppressants and glucocorticoids on the mechanisms of anti-infective protection.
Aim. To highlight the problem of RD and concomitant viral infection which becomes critical in the era of COVID‑19.
Results. According to the current national guidelines for the management of patients with COVID‑19, patients with RD represent an increased risk group for the adverse course of coronavirus infection. Presented article provides basic information on the use of interleukin‑6 (IL‑6) inhibitors in patients with COVID‑19 focusing on the benefit of this therapeutic option in those with prior RD. The article presents an analysis of two clinical cases demonstrating high efficacy and good tolerability of levilimab (Ilsira®) in the treatment of coronavirus pneumoniae in the setting of autoimmune diseases: polymyositis (PM) and rheumatoid arthritis (RA).
Conclusion. Our own clinical experience confirms the feasibility of including an IL‑6 receptor inhibitor in the treatment regimen for coronavirus pneumonia in patients with RD characterized of immune inflammation.
About the Authors
E. V. Kalinina
Volgograd State Medical University
Russian Federation
Russian Federation
Kalinina Elena V., PhD Med, associated professor at Internal Disease Dept
I. V. Lekareva
Volgograd State Medical University
Russian Federation
Russian Federation
Lekareva Irina V., PhD, associated professor of Internal Disease Dept
M. S. Zvonorenko
Volgograd State Medical University
Russian Federation
Russian Federation
Zvonorenko Maxim S., postgraduate student of Internal Disease Dept
A. L. Emelianova
Volgograd State Medical University
Russian Federation
Russian Federation
Emelyanova Anna L., PhD, associated professor of Internal Disease Dept
I. V. Kostryukova
Volgograd State Medical University
Russian Federation
Russian Federation
Kostryukova Irina V., PhD, associated professor of Internal Disease Dept
E. V. Scherbinina
Volgograd Clinical Hospital No. 4
Russian Federation
Russian Federation
Shcherbinina Elena V., head of Hospital
A. R. Babaeva
Volgograd State Medical University
Russian Federation
Russian Federation
Babaeva Aida R., PhD Med, professor, head of Internal Disease Dept
References
1. Prevention, diagnostics and treatment of novel coronavirus infection. Temporary methodical recommendations. Version 10 (08.02.2021). (In Russ.; abstr. in Engl.)
2. Prevention, diagnostics and treatment of novel coronavirus infection. Temporary methodical recommendations. Version 9 (26.10.2021). (In Russ.; abstr. in Engl.)
3. B. S. Belov, A.M. Leela COVID 19 and Rheumatology: One Year Later. Scientific and practical rheumatology. 2021; 59 (1): 31–36.
4. Russian clinical guidelines «Rheumatology», edited by Academician E. L. Nasonov. 2020.
5. A. L. Vertkin. Comorbidity: history, recent views, prevention and treatment. Moscow State Medical and Stomatological University n.a. A.I. Evdokimov. Moscow, Russia Cardiovascular Therapy and Prevention, 2015; 14 (2): 74–79.
6. E. L. Nasonov, A.V. Gordeev, E.A. Galushko. Rheumatic diseases and multimorbidity. Therapeutic archive 2015; (5): 4–9.
7. T.V. Popkova, D.S. Novikova, E.L. Nasonov. Cardiovascular diseases in rheumatoid arthritis: new data. Scientific and Practical Rheumatology. 2016; 54 (2): 122–128.
8. Bassetti M. The Novel Chinese Coronavirus (2019-nCoV) Infections: challenges for fighting the storm. URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13209. https://doi.org/10.1111/eci.13209
9. Canada.ca. 2019 novel coronavirus: Symptoms and treatment. The official website of the Government of Canada. URL: www.canada.ca/en/public-health/ services/diseases/2019-novel-coronavirusinfection/symptoms.html.
10. World Health Organization. Statement on the second meeting of the International Health Regulations (2005). Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Published January 30, 2020.
11. Инструкция по медицинскому применению препарата Илсира® (левилимаб) ЛП 006244 от 22.12.2020 https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=3003f770–1557–4b3b 98bf 47f3a95eafeb&t= Instructions for medical use of the drug Ilsira® (Levilimab) LP 006244 dated 12.22.2020 https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3003f770– 1557–4b3b 98bf 47f3a95eafeb&t=
12. РКИ № 176 (22.04.2020) https://grls.rosminzdrav.ru/CIPermissionMini.aspx? CIStatementGUID=6ca5d253–9fd0–4b84–832a-b6470f56 3874&CIPermGUID=9DDD 0EEC 7562–4CE 3–8616–3D 2F6646A341 RCT No. 176 (04/22/2020) https://grls.rosminzdrav.ru/CIPermissionMini. aspx? CIStatementGUID=6ca5d253–9fd0–4b84–832a-b6470f563874&CIPermGUID=9DDD0EEC 7562–4CE3–6416–3D2F
Review
For citations:
Kalinina E.V., Lekareva I.V., Zvonorenko M.S., Emelianova A.L., Kostryukova I.V., Scherbinina E.V., Babaeva A.R. Rheumatic diseases and coronavirus infection: levilimab use experience. Medical alphabet. 2021;(16):7-12. (In Russ.) https://doi.org/10.33667/2078-5631-2021-16-7-12
Views:
405
Email this article 